Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2146963
Max Phase: Preclinical
Molecular Formula: C60H94N14O10
Molecular Weight: 1171.50
Molecule Type: Protein
Associated Items:
ID: ALA2146963
Max Phase: Preclinical
Molecular Formula: C60H94N14O10
Molecular Weight: 1171.50
Molecule Type: Protein
Associated Items:
Canonical SMILES: CC(C)C[C@@H]1NC(=O)[C@H](CCCN)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CCCN)NC1=O
Standard InChI: InChI=1S/C60H94N14O10/c1-37(2)33-45-55(79)65-41(21-11-27-61)53(77)71-47(35-39-17-7-5-8-18-39)59(83)74-32-16-26-50(74)58(82)68-44(24-14-30-64)52(76)70-46(34-38(3)4)56(80)66-42(22-12-28-62)54(78)72-48(36-40-19-9-6-10-20-40)60(84)73-31-15-25-49(73)57(81)67-43(23-13-29-63)51(75)69-45/h5-10,17-20,37-38,41-50H,11-16,21-36,61-64H2,1-4H3,(H,65,79)(H,66,80)(H,67,81)(H,68,82)(H,69,75)(H,70,76)(H,71,77)(H,72,78)/t41-,42-,43-,44-,45-,46-,47+,48+,49-,50-/m0/s1
Standard InChI Key: IXJNXHQZEDDPLD-KIFFCGDGSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Protein | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1171.50 | Molecular Weight (Monoisotopic): 1170.7277 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Kapoerchan VV, Knijnenburg AD, Keizer P, Spalburg E, de Neeling AJ, Mars-Groenendijk RH, Noort D, Otero JM, Llamas-Saiz AL, van Raaij MJ, van der Marel GA, Overkleeft HS, Overhand M.. (2012) 'Inverted' analogs of the antibiotic gramicidin S with an improved biological profile., 20 (20): [PMID:22989907] [10.1016/j.bmc.2012.08.038] |
Source(1):